|
1. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EM. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-44
2. Nussbaum RL., Christopher EE. (2003) Alzheimer's Disease and Parkinson's Disease. N Engl J Med. 348, 1356-1364
3.ReddyPH. (2006)Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem. 96, 1-13
4. Reddy PH., Beal MF. (2005) Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev.49, 618-32
5. Selkoe DJ. (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 81, 741-66
6. Reddy PH., McWeeney S. (2005) Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiol Aging. ( in Press )
7. Tanzi RE., Bertram L. (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 120, 545-55
8. Neef D., Walling AD. (2006) Dementia with Lewy bodies: an emerging disease. Am Fam Physician. 73, 1223-9
9. Lolli F., Mazzanti B., Rovero P., Papini AM. (2003) Synthetic peptides in the diagnosis of neurological diseases. Curr Protein Pept Sci. 4, 277-84
10. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 13, 45-53
11. Esler WP., Wolfe MS. (2001) A Portrait of Alzheimer Secretases--New Features and Familiar Faces. Science. 293, 1449-54
12. McLaurin J., Franklin T., Chakrabartty A., Fraser PE. (1998) Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. J Mol Biol.278, 183-94
13. Yang DS., Yip CM., Huang TH., Chakrabartty A., Fraser PE. (1999) Manipulating the amyloid-beta aggregation pathway with chemical chaperones. J Biol Chem. 274, 32970-4
14. Defelice FG., Ferreira ST. (2002) Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer’s disease. An Acad Bras Cienc. 74, 265-84
15. Beking K., Hao X., Basak S., Basak A. ( 2005) Modulatory Effects of pH, Cu+2 and Sheet Breakers on Aggregation of Amyloid Peptides. Protein Pept Lett. 12, 197-202
16. Fraser PE., Nguyen JT., Surewicz WK., Kirschner DA. (1991) pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys J. 60, 1190-201
17. Bohrmann B., Tjernberg L., Kuner P., Poli S., Levet-Trafit B., Naslund J., Richards G., Huber W., Dobeli H., Nordstedt C. (1999) Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. J Biol Chem. 274, 15990-5
18. Wood SJ., Chan W., Wetzel R. (1996) An ApoE-Abeta inhibition complex in Abeta fibril extension. Chem Biol. 3, 949-956
19. Cohlberg JA., Li J., Uversky VN., Fink AL. (2002) Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry. 41, 1502-11
20. Yang DS., Serpell LC., Yip CM., McLaurin J., Chrishti MA., Horne P., Boudreau L., Kisilevsky R., Westaway D., Fraser PE. (2001) Assembly of Alzheimer's amyloid-beta fibrils and approaches for therapeutic intervention. Amyloid. 8 Suppl 1:10-9
21. Drouet B., Fifre A., Pincon-Raymond M., Vandekerckhove J., Rosseneu M., Gueant JL., Chambaz J., Pillot T. (2001) ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide. J Neurochem. 76, 117-27.
22. Koldamova RP., Lefterov IM., Lefterova MI., Lazo JS. (2001) Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry. 40, 3553-60
23. Webster S., Rogers J. (1996) Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. J Neurosci Res. 46, 58-66.
24. Webster S., Glabe C., Rogers J. (1995) Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun. 217, 869-75.
25. Webster S., O'Barr S., Rogers J. (1994) Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q. J Neurosci Res. 39, 448-56.
26. Alvarez A., Opazo C., Alarcon R., Garrido J., Inestrosa NC. (1997) Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J Mol Biol. 272, 348-61
27. Talesa VN. (2001) Acetylcholinesterase in Alzheimer's disease. Mech Ageing Dev. 122, 1961-1969
28. Monji A, Tashiro K, Yoshida I, Hayashi Y, Tashiro N. (1998) Laminin inhibits A beta 40 fibril formation promoted by apolipoprotein E4 in vitro. Brain Res. 796, 171-5
29. McLaurin J., Golomb R., Jurewicz A., Antel JP., Fraser PE. (2000) Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. J Biol Chem. 275, 18495-18502
30. Zhao H., Tuominen EK., Kinnunen PK. (2004) Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. Biochemistry. 43,10302-7
31. McLaurin J., Franklin T., Chakrabartty A., Fraser PE. (1998) Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. J Mol Biol. 278, 183-94
32. Yanagisawa K., Odaka A., Suzuki N., Ihara Y. (1995) GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat Med. 1, 1062-6
33. McLaurin J., Franklin T., Fraser PE., Chakrabartty A. (1998) Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides. J Biol Chem. 273, 4506-15
34. Ricchelli F., Drago D., Filippi B., Tognon G., Zatta P. (2005) Aluminum-triggered structural modifications and aggregation of beta-amyloids. Cell Mol Life Sci. 62, 1724-33
35. Lovell MA., Robertson JD., Teesdale WJ., Campbell JL., Markesbery WR. (1998) Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci. 158, 47-52
36. Brieland JK., Fantone JC. (1991) Ferrous iron release from transferrin by human neutrophil-derived superoxide anion: effect of pH and iron saturation. Arch Biochem Biophys. 284, 78-83
37. Cherny RA., Legg JT., McLean CA., Fairlie DP., Huang X., Atwood CS., Beyreuther K., Tanzi RE., Masters CL., Bush AI. (1999) Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem. 274, 23223-8
38. Cherny RA., Barnham KJ., Lynch T., Volitakis I., Li QX., McLean CA., Multhaup G., Beyreuther K., Tanzi RE., Masters CL., Bush AI. (2000) Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol. 130, 209-16
39. Liu ST., Howlett G., Barrow CJ. (1999) Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease. Biochemistry. 38, 9373-8
40. Moir RD., Atwood CS., Romano DM., Laurans MH., Huang X., Bush AI., Smith JD., Tanzi RE. (1999) Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. Biochemistry. 38, 4595-4603
41. Drouet B., Fifre A., Pincon-Raymond M., Vandekerckhove J., Rosseneu M., Gueant JL., Chambaz J., Pillot T. (2001) ApoE protects cortical neurones against neurotoxicity induced by the nonfibrillar C-terminal domain of the amyloid-beta peptide. J Neurochem. 76, 117-127
42. McLaurin J., Chakrabartty A. (1997) Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid membranes. Eur J Biochem. 245, 355-363
43. McLaurin J., Chakrabartty A. (1996) Membrane disruption byAlzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J Biol Chem. 271, 26482-26489
44. Kiuchi Y., Isobe Y., Fukushima K. (2001) Entactin induced inhibition of human amyloid beta-protein fibril formation in vitro. Neurosci Lett. 305, 119-122
|